DOI:
10.1055/s-00000075
Seminars in Respiratory and Critical Care Medicine
LinksClose Window
References
Enblad G, Hagberg H, Erlanson M. , et al.
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
Blood 2004;
103 (08) 2920-2924
We do not assume any responsibility for the contents of the web pages of other providers.